{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:09:25Z","timestamp":1782634165986,"version":"3.54.5"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cegh.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Epidemiology and Global Health"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.cegh.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T21:29:47Z","timestamp":1595971787000},"page":"90-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"special_numbering":"C","title":["Antivirals for COVID-19: A critical review"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-2948","authenticated-orcid":false,"given":"Andri","family":"Frediansyah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-5547","authenticated-orcid":false,"given":"Ruchi","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-3746","authenticated-orcid":false,"given":"Khan","family":"Sharun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Dhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7630-8413","authenticated-orcid":false,"given":"Harapan","family":"Harapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cegh.2020.07.006_bib1","series-title":"Pandemic Coronavirus Disease (COVID-19): Challenges and A Global Perspective","first-page":"2020040469","author":"Malik","year":"2020"},{"issue":"2","key":"10.1016\/j.cegh.2020.07.006_bib2","first-page":"147","article-title":"The 2019 novel coronavirus disease (COVID-19) pandemic: a review of the current evidence","volume":"151","author":"Chatterjee","year":"2020","journal-title":"Indian J Med Res"},{"issue":"5","key":"10.1016\/j.cegh.2020.07.006_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cegh.2020.07.006_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2020.03.019","article-title":"Coronavirus disease 2019 (COVID-19): a literature review","author":"Harapan","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.cegh.2020.07.006_bib5","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.tmaid.2020.101623","article-title":"Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis","author":"Rodriguez-Morales","year":"2020","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.cegh.2020.07.006_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2123","article-title":"Immunopathology and immunotherapeutic strategies in SARS-CoV-2 infection","author":"Keam","year":"2020","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib7","article-title":"The reproductive number of COVID-19 is higher compared to SARS coronavirus","author":"Liu","year":"2020","journal-title":"J Trav Med"},{"key":"10.1016\/j.cegh.2020.07.006_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cegh.2020.07.006_bib9","series-title":"Coronaviruses: An Overview of Their Replication and Pathogenesis","first-page":"1","author":"Fehr","year":"2015"},{"key":"10.1016\/j.cegh.2020.07.006_bib10","series-title":"Fenner and White's Medical Virology","author":"Burrell","year":"2016"},{"key":"10.1016\/j.cegh.2020.07.006_bib11","author":"Chatterjee"},{"key":"10.1016\/j.cegh.2020.07.006_bib12","first-page":"S142","article-title":"Receptor-binding domain as a target for developing SARS vaccines","volume":"5","author":"Zhu","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cegh.2020.07.006_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.cegh.2020.07.006_bib14","series-title":"Coronavirus SARS-CoV-2: Analysis of Subgenomic mRNA Transcription, 3CLpro and PL2pro Protease Cleavage Sites and Protein Synthesis","author":"Pascual","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib15","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.vaccine.2020.01.072","article-title":"Parents' hesitancy towards vaccination in Indonesia: a cross-sectional study in Indonesia","volume":"38","author":"Yufika","year":"2020","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.cegh.2020.07.006_bib16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cmi.2020.04.001","article-title":"Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay","volume":"26","author":"Yan","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cegh.2020.07.006_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.cegh.2020.07.006_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cegh.2020.07.006_bib19","series-title":"SARS-CoV-2\/COVID-19 and advances in developing potential therapeutics and vaccines to counter This emerging pandemic virus\u2013a review","author":"Rabaan","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"issue":"15","key":"10.1016\/j.cegh.2020.07.006_bib21","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","volume":"323","author":"Young","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cegh.2020.07.006_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.cegh.2020.07.006_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.cegh.2020.07.006_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.01.007","article-title":"Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona","volume":"320","author":"Li","year":"2020","journal-title":"J Contr Release"},{"issue":"2","key":"10.1016\/j.cegh.2020.07.006_bib25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1021\/acs.biomac.9b01650","article-title":"Human plasma protein corona of abeta amyloid and its impact on islet amyloid polypeptide cross-seeding","volume":"21","author":"Nandakumar","year":"2020","journal-title":"Biomacromolecules"},{"issue":"2","key":"10.1016\/j.cegh.2020.07.006_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cegh.2020.07.006_bib27","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cegh.2020.07.006_bib28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jmv.25726","article-title":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2","volume":"92","author":"Liu","year":"2020","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.cegh.2020.07.006_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cegh.2020.07.006_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u0393\u00c7\u00f4an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Military Med Res"},{"key":"10.1016\/j.cegh.2020.07.006_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cegh.2020.07.006_bib32","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1073\/pnas.0800502105","article-title":"Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution","volume":"105","author":"Zeng","year":"2008","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.cegh.2020.07.006_bib33","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cegh.2020.07.006_bib34","series-title":"A Novel Coronavirus 2019 Linked with Pneumonia in China: Current Status and Future Prospects","author":"Ahmed","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib35","series-title":"A Web-Based Platform on COVID-19 to Maintain Predicted Diagnostic, Drug and Vaccine Candidates","author":"Patiyal","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/MRA.00169-20","article-title":"Complete genome sequence of a 2019 novel coronavirus (SARS-CoV-2) strain isolated in Nepal","volume":"9","author":"Sah","year":"2020","journal-title":"Microbiol Resour Announc"},{"issue":"7","key":"10.1016\/j.cegh.2020.07.006_bib37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.cub.2020.03.022","article-title":"Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak","volume":"30","author":"Zhang","year":"2020","journal-title":"Curr Biol"},{"key":"10.1016\/j.cegh.2020.07.006_bib38","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J"},{"key":"10.1016\/j.cegh.2020.07.006_bib39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cegh.2020.07.006_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12250-015-3711-3","article-title":"Recent progress in the discovery of inhibitors targeting coronavirus proteases","volume":"31","author":"Wang","year":"2016","journal-title":"Virol Sin"},{"key":"10.1016\/j.cegh.2020.07.006_bib41","doi-asserted-by":"crossref","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","author":"Shannon","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.cegh.2020.07.006_bib42","doi-asserted-by":"crossref","first-page":"E3900","DOI":"10.1073\/pnas.1323705111","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2014","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.cegh.2020.07.006_bib43","first-page":"E162","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Fo","year":"2018","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.cegh.2020.07.006_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrmicro2692","article-title":"The dependence of viral RNA replication on co-opted host factors","volume":"10","author":"Nagy","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cegh.2020.07.006_bib45","series-title":"Topoisomerase III-Beta Is Required for Efficient Replication of Positive-Sense RNA Viruses","author":"Prasanth","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib46","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1099\/vir.0.80671-0","article-title":"Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E","volume":"86","author":"Nal","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2013.12.009","article-title":"The SARS coronavirus nucleocapsid protein\u0393\u00c7\u00f4forms and functions","volume":"103","author":"Chang","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.cegh.2020.07.006_bib48","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1128\/jvi.68.10.6523-6534.1994","article-title":"Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding","volume":"68","author":"Klumperman","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib49","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures","volume":"53","author":"Khamitov","year":"2008","journal-title":"Vopr Virusol"},{"key":"10.1016\/j.cegh.2020.07.006_bib50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","article-title":"Potential interventions for novel coronavirus in China: a systematic review","volume":"92","author":"Zhang","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib51","doi-asserted-by":"crossref","first-page":"108409","DOI":"10.1016\/j.clim.2020.108409","article-title":"Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic","author":"Gasmi","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cegh.2020.07.006_bib52","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cegh.2020.07.006_bib53","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cegh.2020.07.006_bib54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.cegh.2020.07.006_bib55","doi-asserted-by":"crossref","first-page":"105967","DOI":"10.1016\/j.ijantimicag.2020.105967","article-title":"Janus kinase inhibitor-not an ideal option for management OF covid 19","volume":"55","author":"Praveen","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cegh.2020.07.006_bib56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.cegh.2020.07.006_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","author":"Zhua","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.cegh.2020.07.006_bib58","series-title":"Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","author":"Jieming","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib59","series-title":"The Efficacy of Lopinavir Plus Ritonavir and Arbidol against Novel Coronavirus Infection (ELACOI)","author":"Li","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib60","doi-asserted-by":"crossref","DOI":"10.1007\/s11739-020-02345-9","article-title":"Camostat mesilate therapy for COVID-19","author":"Uno","year":"2020","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cegh.2020.07.006_bib61","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib62","series-title":"The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19)","author":"\u00d8stergaard","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib63","series-title":"Combination Therapy with Camostat Mesilate + Hydroxychloroquine for COVID-19 (CLOCC)","author":"Heinrich-Heine University","year":"2020"},{"issue":"6","key":"10.1016\/j.cegh.2020.07.006_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.cegh.2020.07.006_bib65","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/jth.14858","article-title":"Potential of heparin and nafamostat combination therapy for COVID-19","volume":"18","author":"Asakura","year":"2020","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cegh.2020.07.006_bib66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cegh.2020.07.006_bib67","series-title":"Atazanavir Inhibits SARS-CoV-2 Replication and Pro-inflammatory Cytokine Production","author":"Fintelman-Rodrigues","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib68","article-title":"Fast identification of possible drug treatment of coronavirus disease -19 (COVID-19) through computational drug repurposing study","author":"Wang","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.cegh.2020.07.006_bib69","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","author":"Choy","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.cegh.2020.07.006_bib70","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijid.2020.03.013","article-title":"Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression","volume":"95","author":"Liu","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.cegh.2020.07.006_bib71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jgg.2020.02.001","article-title":"Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines","volume":"47","author":"Liu","year":"2020","journal-title":"J Gene Genom"},{"key":"10.1016\/j.cegh.2020.07.006_bib72","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.cegh.2020.07.006_bib73","article-title":"Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J Kor Med Sci"},{"issue":"19","key":"10.1016\/j.cegh.2020.07.006_bib74","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cegh.2020.07.006_bib75","series-title":"\u201cSolidarity\u201d Clinical Trial for COVID-19 Treatments","author":"WHO","year":"2020"},{"issue":"1","key":"10.1016\/j.cegh.2020.07.006_bib76","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.cegh.2020.07.006_bib77","series-title":"Information for Clinicians on Therapeutic Options for Patients with COVID-19","author":"CDC CfDCaP","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib78","series-title":"COVID-19 Science Report: Therapeutics","author":"SSH-SPH NSSHSoPH","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib79","series-title":"Concept of Antiviral Drug Treatment for COVID-19","author":"Ministry of Health LaW","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib80","series-title":"International Pulmonologist's Consensus on COVID-19","author":"IP IP","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib81","series-title":"Evaluating and Comparing the Safety and Efficiency of ASC09\/Ritonavir and Lopinavir\/Ritonavir for Novel Coronavirus Infection","author":"Qiu","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib82","doi-asserted-by":"crossref","first-page":"m641","DOI":"10.1136\/bmj.m641","article-title":"Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cegh.2020.07.006_bib83","series-title":"Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients with Pneumonia by COVID-19 (Covid-19HUF)","author":"Bernal","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib84","series-title":"Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)","author":"Ader","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib85","series-title":"Lopinavir\/Ritonavir, Ribavirin and IFN-Beta Combination for nCoV Treatment","author":"Hung","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib86","series-title":"Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial (THDMS-COVID-19)","author":"Kongsaengdao","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib87","series-title":"COVID MED Trial - Comparison of Therapeutics for Hospitalized Patients Infected with SARS-CoV-2 (COVIDMED)","author":"Freilich","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib88","first-page":"12","article-title":"National institute for the infectious diseases \u0393\u00c7\u00a3L. Spallanzani\u0393\u00c7\u00a5, IRCCS. Recommendations for COVID-19 clinical management","author":"Nicastri","year":"2020","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.cegh.2020.07.006_bib89","series-title":"Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 (DC-COVID-19)","author":"Lu","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib90","author":"Kumar"},{"key":"10.1016\/j.cegh.2020.07.006_bib91","doi-asserted-by":"crossref","first-page":"104826","DOI":"10.1016\/j.phrs.2020.104826","article-title":"Darunavir does not prevent SARS-CoV-2 infection in HIV patients","author":"Riva","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cegh.2020.07.006_bib92","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/QAD.0b013e32832ba904","article-title":"Effects of switching from lopinavir\/ritonavir to atazanavir\/ritonavir on muscle glucose uptake and visceral fat in HIV infected patients","volume":"23","author":"Stanley","year":"2009","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.cegh.2020.07.006_bib93","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","volume":"20","author":"Noor","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.cegh.2020.07.006_bib94","doi-asserted-by":"crossref","first-page":"101646","DOI":"10.1016\/j.tmaid.2020.101646","article-title":"A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease","author":"Hall","year":"2020","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.cegh.2020.07.006_bib95","series-title":"Nelfinavir Inhibits Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Vitro","author":"Yamamoto","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib96","first-page":"1","article-title":"Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase","author":"Khan","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.cegh.2020.07.006_bib97","article-title":"Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants","author":"Ul Qamar","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.cegh.2020.07.006_bib98","series-title":"Remdesivir as a Possible Therapeutic Option for the COVID-19. Travel Medicine and Infectious Disease","author":"Al-Tawfiq","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib99","doi-asserted-by":"crossref","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cegh.2020.07.006_bib100","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cegh.2020.07.006_bib101","doi-asserted-by":"crossref","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.cegh.2020.07.006_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.cegh.2020.07.006_bib103","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.onehlt.2020.100128","article-title":"Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses","author":"Amirian","year":"2020","journal-title":"One Health"},{"issue":"396","key":"10.1016\/j.cegh.2020.07.006_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.cegh.2020.07.006_bib105","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMp2000929","article-title":"A novel coronavirus emerging in China - key questions for impact assessment","volume":"382","author":"Munster","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cegh.2020.07.006_bib106","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.cegh.2020.07.006_bib107","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"issue":"7798","key":"10.1016\/j.cegh.2020.07.006_bib108","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cegh.2020.07.006_bib109","series-title":"Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\u2122) in Participants with Severe Coronavirus Disease (COVID-19)","author":"Gilead Sciences","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib110","series-title":"The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients","author":"Aukrust","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib111","series-title":"Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)","author":"Ader","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib112","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cegh.2020.07.006_bib113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/d41586-020-00307-x","article-title":"Calling all coronavirus researchers: keep sharing, stay open","volume":"578","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.cegh.2020.07.006_bib114","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B"},{"key":"10.1016\/j.cegh.2020.07.006_bib115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B"},{"key":"10.1016\/j.cegh.2020.07.006_bib116","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cegh.2020.07.006_bib117","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","author":"Zhai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cegh.2020.07.006_bib118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.cegh.2020.07.006_bib119","series-title":"Clinical Study for Safety and Efficacy of Favipiravir in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","author":"Xuejiao","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.cegh.2020.07.006_bib121","series-title":"Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial","author":"Chen","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib122","series-title":"Tata Laksana Pasien Covid-19","author":"ISR","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib123","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.cegh.2020.07.006_bib124","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jmv.25798","article-title":"Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19","volume":"92","author":"Khalili","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib126","series-title":"Lopinavir\/Ritonavir, Ribavirin and IFN-Beta Combination for nCoV Treatment","author":"The University of Hong Kong","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib127","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Therapeut"},{"key":"10.1016\/j.cegh.2020.07.006_bib128","doi-asserted-by":"crossref","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.cegh.2020.07.006_bib129","series-title":"Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking","author":"Chang","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.285.6.748","article-title":"Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial","volume":"285","author":"Welliver","year":"2001","journal-title":"Jama"},{"key":"10.1016\/j.cegh.2020.07.006_bib131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.cegh.2020.07.006_bib132","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/clinchem\/hvaa029","article-title":"Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia","volume":"66","author":"Chu","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.cegh.2020.07.006_bib133","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cegh.2020.07.006_bib134","first-page":"1","article-title":"Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19","author":"Muralidharan","year":"2020","journal-title":"J Biomol Struct Dyn"},{"issue":"6","key":"10.1016\/j.cegh.2020.07.006_bib135","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1473-3099(20)30231-0","article-title":"The first COVID-19 case in Afghanistan acquired from Iran","volume":"20","author":"Mousavi","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cegh.2020.07.006_bib136","article-title":"Longitudinal CT findings in COVID-19 pneumonia: case presenting organizing pneumonia pattern","volume":"2","author":"Wu","year":"2020","journal-title":"Radiology: Cardiothorac Imag"},{"key":"10.1016\/j.cegh.2020.07.006_bib137","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1099\/0022-1317-38-1-97","article-title":"On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride","volume":"38","author":"Skehel","year":"1978","journal-title":"J Gen Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib138","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0014-5793(02)03851-6","article-title":"The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine","volume":"535","author":"Griffin","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cegh.2020.07.006_bib139","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/AAC.4.4.421","article-title":"In vitro antiviral activity and preliminary clinical trials of a new adamantane compound","volume":"4","author":"Mathur","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cegh.2020.07.006_bib140","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1110\/ps.062730007","article-title":"Conductance and amantadine binding of a pore formed by a lysine\u0393\u00c7\u00c9flanked transmembrane domain of SARS coronavirus envelope protein","volume":"16","author":"Torres","year":"2007","journal-title":"Protein Sci"},{"key":"10.1016\/j.cegh.2020.07.006_bib141","series-title":"Amantadine Disrupts Lysosomal Gene Expression; Potential Therapy for COVID19","author":"Smieszek","year":"2020"},{"issue":"6","key":"10.1016\/j.cegh.2020.07.006_bib142","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jmv.25752","article-title":"Potentially repurposing adamantanes for COVID-19","volume":"92","author":"Cimolai","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.cegh.2020.07.006_bib143","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.antiviral.2012.06.008","article-title":"Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?","volume":"95","author":"Caly","year":"2012","journal-title":"Antivir Res"},{"issue":"6","key":"10.1016\/j.cegh.2020.07.006_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.04.017","article-title":"Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and treatment?","volume":"82","author":"Patri","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cegh.2020.07.006_bib145","series-title":"Ivermectin as a Potential COVID-19 Treatment from the Pharmacokinetic Point of View","author":"Momekov","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib146","series-title":"Usefulness of ivermectin in COVID-19 illness","author":"Patel","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib147","article-title":"The trial of chloroquine in the treatment of corona virus disease 2019 COVID-19 and its research progress in forensic toxicology","volume":"36","author":"Duan","year":"2020","journal-title":"Fa Yi Xue Za Zhi"},{"issue":"2","key":"10.1016\/j.cegh.2020.07.006_bib148","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5582\/bst.2020.03072","article-title":"Update on use of chloroquine\/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Gao","year":"2020","journal-title":"BioSci Trends"},{"key":"10.1016\/j.cegh.2020.07.006_bib149","doi-asserted-by":"crossref","first-page":"104904","DOI":"10.1016\/j.phrs.2020.104904","article-title":"The possible mechanisms of action of 4-aminoquinolines (chloroquine\/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): a role for iron homeostasis?","volume":"158","author":"Quiros Roldan","year":"2020","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.cegh.2020.07.006_bib150","doi-asserted-by":"crossref","first-page":"105960","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.cegh.2020.07.006_bib151","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5582\/ddt.2020.03010","article-title":"Is GSK3\u03b2 a molecular target of chloroquine treatment against COVID-19?","volume":"14","author":"Embi","year":"2020","journal-title":"Drug Discov Therapeut"},{"issue":"8","key":"10.1016\/j.cegh.2020.07.006_bib152","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25081834","article-title":"COVID-19, chloroquine repurposing, and cardiac safety concern: chirality might help","volume":"25","author":"Lentini","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.cegh.2020.07.006_bib153","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1016\/S2214-109X(20)30114-5","article-title":"Use of antiviral drugs to reduce COVID-19 transmission","volume":"8","author":"Mitj\u00e0","year":"2020","journal-title":"Lancet Global Health"},{"issue":"16","key":"10.1016\/j.cegh.2020.07.006_bib154","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.cegh.2020.07.006_bib155","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cegh.2020.07.006_bib156","series-title":"COVID-19 Convalescent Plasma - Emergency INDs","author":"Investigational","year":"2020"},{"key":"10.1016\/j.cegh.2020.07.006_bib157","series-title":"A Prospective\/retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","author":"Ning","year":"2020"},{"issue":"5","key":"10.1016\/j.cegh.2020.07.006_bib158","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cegh.2020.07.006_bib159","series-title":"Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19)","author":"Perrone","year":"2020"}],"container-title":["Clinical Epidemiology and Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213398420301767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213398420301767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:49:34Z","timestamp":1761986974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213398420301767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":159,"alternative-id":["S2213398420301767"],"URL":"https:\/\/doi.org\/10.1016\/j.cegh.2020.07.006","relation":{},"ISSN":["2213-3984"],"issn-type":[{"value":"2213-3984","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antivirals for COVID-19: A critical review","name":"articletitle","label":"Article Title"},{"value":"Clinical Epidemiology and Global Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cegh.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier, a division of RELX India, Pvt. Ltd on behalf of INDIACLEN.","name":"copyright","label":"Copyright"}]}}